Dr. Vincent Fradet (MD, PhD, FRCSC) is an uro-oncologist with a focused clinical practice at CHU de Québec-Laval University. He completed his medical training at Université de Montréal with an MD and residency in urology. He pursued with 5 years of subspecialty and research training. He obtained his uro-oncology accreditation from the Society of Urologic Oncology at the University of California, in San Francisco (UCSF) and completed a PhD in Clinical Research/Epidemiolgy (University de Montréal). Dr. Fradet has been an Associate Professor at Laval University since 2009, and is a regular researcher at the Laval University Cancer Research Center and at INAF (Institute for Nutrition and functional Food).

Dr. Fradet’s research goal is to improve our understanding of the links between lifestyle factors, including dietary omega-3 fatty acids and exercise, quality of life parameters, inflammation, and oncogenic pathways in prostate cancer, to progressively develop personalized preventive and treatment strategies. To that end, Dr. Fradet has built a unique biobank of bio-samples, developed pre-clinical models (mouse and primary cells in culture) and is running some clinical studies. All the epidemiological, clinical, and molecular (translational) projects led by his team are focused on improving our understanding of the biological mechanisms and the impact on quality of life of prostate cancer, as well as on developing biomarkers (urinary, blood, epigenetics, molecular and/or cellular) to be used in future intervention studies to stratify or select and monitor patients.

Hôpital de l'Enfant-Jésus
1401, 18e rue
G4.610
Québec, QC
Canada G1J 1Z4
+1 418-525-4444, extension 67694
Vincent.Fradet@crchudeque... vincent.fradet@fmed.ulava...

Latest news

65 entries « ‹ 2 of 7 › »

Otis-Chapados S, Goulet CR, Dubois G, Lavallée É, Dujardin T, Fradet Y, Lacombe L, Lodde M, Tiguert R, Toren P, Fradet V, Beauregard JM, Buteau FA, Pouliot F

18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy

Journal Article

Can Urol Assoc J, 15 (10), 2021.

Abstract | Links:

Fervaha G, Izard JP, Tripp DA, Aghel N, Shayegan B, Klotz L, Niazi T, Fradet V, Taussky D, Lavallee LT, Hamilton RJ, Brown I, Chin J, Gopaul D, Violette PD, Davis MK, Karampatos S, Pinthus JH, Leong DP, Siemens DR,

Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study

Journal Article

Can Urol Assoc J, 15 (6), 2021.

Abstract | Links:

Gevariya N, Lachance G, Robitaille K, Joly Beauparlant C, Beaudoin L, Fournier É, Fradet Y, Droit A, Julien P, Marette A, Bergeron A, Fradet V

Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity

Journal Article

Mol Cancer Res, 19 (3), 2021.

Abstract | Links:

Bilodeau JF, Gevariya N, Larose J, Robitaille K, Roy J, Oger C, Galano JM, Bergeron A, Durand T, Fradet Y, Julien P, Fradet V

Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth

Journal Article

Prostaglandins Leukot Essent Fatty Acids, 164 , 2021.

Abstract | Links:

Loubersac T, Nguile-Makao M, Pouliot F, Fradet V, Toren P

Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study

Journal Article

Eur Urol Oncol, 3 (3), 2020.

Abstract | Links:

Koti M, Berman DM, Siemens DR, Lange D, Wang E, Toren P, Eigl BJ, Hardy C, Purves R, Fradet V, Fradet Y, Mansure J, Kassouf W, Black PC,

Building a Canadian Translational Bladder Cancer Research Network

Journal Article

Can Urol Assoc J, 14 (10), 2020.

| Links:

Gotto G, Drachenberg DE, Chin J, Casey R, Fradet V, Sabbagh R, Shayegan B, Rendon RA, Danielson B, Camacho F, Zardan A, Plante R, Hew H, Chan K, Feifer A

Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC

Journal Article

Can Urol Assoc J, 14 (12), 2020.

Abstract | Links:

Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, Klotz L, Brown I, Chin J, Lavallee L, Mousavi N, Luke P, Lukka H, Gopaul D, Violette P, Hamilton RJ, Davis MK, Karampatos S, Mian R, Delouya G, Fradet Y, Mukherjee S, Conen D, Chen-Tournoux A, Johnson C, Bessissow A, Dresser G, Hameed AK, Abdel-Qadir H, Sener A, Pal R, Devereaux PJ, Pinthus J

Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study

Journal Article

J Urol, 203 (6), 2020.

Abstract | Links:

Nguile-Makao M, Allard MA, Bairati I, Meyer F, Robitaille K, Fradet Y, Lacombe L, Pouliot F, Toren P, Duchesne T, Fradet V

Charlson Comorbidity Index as a Predictor of Cancer Mortality Beyond 10 Years after Radical Prostatectomy

Journal Article

Clin Oncol (Belmont), 4 , 2019.

| Links:

Lavallée E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F

Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration

Journal Article

Eur Urol Focus, 5 (6), 2019.

Abstract | Links:

65 entries « ‹ 2 of 7 › »
Signaler des ajouts ou des modifications

Active projects

  • Bactériophages et immunothérapie en cancer de la prostate, from 2023-05-03 to 2024-03-31
  • En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers, from 2020-06-01 to 2023-06-30
  • Habitudes de vie, biomarqueurs et risque de cancer de la prostate, from 2022-04-01 to 2024-03-31
  • Institut sur la nutrition et les aliments fonctionnels (INAF), from 2017-04-01 to 2024-03-31
  • Les habitudes de vie en cancer de la prostate au coeur d’une médecine personnalisée, from 2021-07-01 to 2024-06-30
  • Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma, from 2022-08-01 to 2026-07-31
  • Rôle des habitudes de vie sur le microbiote et la réponse clinique à l’immunothérapie en cancer de la vessie, from 2023-04-20 to 2024-03-31
  • What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer, from 2022-01-15 to 2024-01-14

Recently finished projects

  • Impact of lifestyle on gut barrier function, bacterial translocation and risk of prostate cancer, from 2020-09-01 to 2023-04-30
  • Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions., from 2012-10-01 to 2021-12-31
  • Patrons alimentaires à base de plantes et prévention du cancer de la prostate: une étude de cohorte prospective, from 2020-12-16 to 2022-12-31
  • Prebiotics to enhance immunotherapy response in bladder cancer, from 2019-01-01 to 2021-07-31
Data provided by the Université Laval research projects registery